In our experimental CAR T treatment of GBM xenograft NSG mouse model, we demonstrated that administering a suboptimal number of EGFRvIII CAR T cells had minimal impact on established subcutaneously implanted PDL1–positive D270 GBM tumors. The gene discussed is CD274; the disease is glioblastoma.